This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Opipramol is a medication to treat general anxiety and somatoform disorders.
- Generic Name
- Opipramol
- DrugBank Accession Number
- DB12930
- Background
Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Opipramol (DB12930)
- Weight
- Average: 363.505
Monoisotopic: 363.231062566 - Chemical Formula
- C23H29N3O
- Synonyms
- Opipramol
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Generalized anxiety disorder (gad) •••••••••••• •••••• Treatment of Somatoform disorders •••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Opipramol. Acarbose Opipramol may decrease the hypoglycemic activities of Acarbose. Acebutolol Opipramol may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of gastrointestinal bleeding can be increased when Opipramol is combined with Aceclofenac. Acemetacin The risk or severity of gastrointestinal bleeding can be increased when Opipramol is combined with Acemetacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Opipramol hydrochloride B49OBI656M 909-39-7 DLTOEESOSYKJBK-UHFFFAOYSA-N
Categories
- ATC Codes
- N06AA05 — Opipramol
- Drug Categories
- Adrenergic Agents
- Agents that produce hypertension
- Agents that reduce seizure threshold
- Antidepressive Agents
- Antidepressive Agents, Tricyclic
- Central Nervous System Agents
- Central Nervous System Depressants
- Dibenzazepines
- Heterocyclic Compounds, Fused-Ring
- Membrane Transport Modulators
- Narrow Therapeutic Index Drugs
- Nervous System
- Neurotoxic agents
- Neurotransmitter Agents
- Neurotransmitter Uptake Inhibitors
- Non-Selective Monoamine Reuptake Inhibitors
- Psychoanaleptics
- Psychotropic Drugs
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzazepines
- Sub Class
- Dibenzazepines
- Direct Parent
- Dibenzazepines
- Alternative Parents
- Alkyldiarylamines / N-alkylpiperazines / Azepines / Benzenoids / Trialkylamines / 1,2-aminoalcohols / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- 1,2-aminoalcohol / 1,4-diazinane / Alcohol / Alkanolamine / Alkyldiarylamine / Amine / Aromatic heteropolycyclic compound / Azacycle / Azepine / Benzenoid
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- D23ZXO613C
- CAS number
- 315-72-0
- InChI Key
- YNZFUWZUGRBMHL-UHFFFAOYSA-N
- InChI
- InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2
- IUPAC Name
- 2-[4-(3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}propyl)piperazin-1-yl]ethan-1-ol
- SMILES
- OCCN1CCN(CCCN2C3=CC=CC=C3C=CC3=CC=CC=C23)CC1
References
- General References
- DIMDI Drug Product Information: Opipramol AbZ film-coated tablets [Link]
- External Links
- PubChem Compound
- 9417
- PubChem Substance
- 347829075
- ChemSpider
- 9046
- BindingDB
- 50170636
- 7674
- ChEBI
- 94614
- ChEMBL
- CHEMBL370753
- ZINC
- ZINC000021981303
- PharmGKB
- PA144614922
- Wikipedia
- Opipramol
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Terminated Treatment Anxiety Disorders / Dementia / Depression / Psychosomatic Disorders / Schizophrenia 1 0 Unknown Status Treatment Substance Abuse 1 Not Available Enrolling by Invitation Not Available Altered Mental Status / Cardiovascular Disease (CVD) / Cardiovascular Risk / Hypertension / Sleep Apnea / Sleep Bruxism / Sleep disorders and disturbances / Temporomandibular Disorders (TMD) / Thyroid Dysfunction 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet 50 mg Pill Tablet, film coated Oral 100 MG Tablet, coated Oral 50 MG Tablet, coated Oral Tablet, film coated Oral 50 MG Tablet, film coated Oral 150 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.105 mg/mL ALOGPS logP 3.13 ALOGPS logP 3.24 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 15.59 Chemaxon pKa (Strongest Basic) 7.86 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 29.95 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 114.06 m3·mol-1 Chemaxon Polarizability 42.65 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0009000000-2e45171d743b5d10a583 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0009000000-685eb318c30b0f8f7cec Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-03e9-0289000000-98aa2ccd2b553d5bf919 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-8838485202e46bfa359a Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-03du-0549000000-823baad3ed6e282912e7 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-2379000000-b0bdb8ae32426afb370f Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 204.6662248 predictedDarkChem Lite v0.1.0 [M-H]- 185.06075 predictedDeepCCS 1.0 (2019) [M+H]+ 204.9585248 predictedDarkChem Lite v0.1.0 [M+H]+ 187.50746 predictedDeepCCS 1.0 (2019) [M+Na]+ 204.8338248 predictedDarkChem Lite v0.1.0 [M+Na]+ 195.13696 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 01:22 / Updated at June 12, 2021 10:54